Research development of triple negative breast cancer targeted therapy

Triple negative breast cancer(TNBC) is a subgroup of breast cancers,defined by a lack of the expressions of estrogen,progesterone and HER2 receptors,with its exclusive pathological and molecular biological characteristics.TNBC is associated with increased risk for distant metastases,early recurrence,short lifetime and poorer prognosis than other type of breast cancer.Besides operation,chemotherapy is the major therapy for TNBC.Currently the targeted therapy is applied to clinical therapy gradually,and it might benefit the patients with TNBC.A deeper insight into the targeted therapy of TNBC may lead to improved therapies and better clinical outcomes of the disease.